Lu Jiang-Li, Ye Yun-Lin, Zheng Dan-Dan, Shi Xin-Yu, Hu Li-Ling, Yuan Xiao-Yi, Cai Tao-Nong, Meng Kun, Wen Neng-Qiao, Li Yu-Ying, Wang Ding-Kang, Shi Fu-Jin, Liu Dan-Ya, He Qing-Yu, Qin Zi-Ke, Zhang Chris Zhiyi, Cao Yun
MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangzhou, China.
Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Br J Cancer. 2024 Dec;131(12):1901-1912. doi: 10.1038/s41416-024-02883-5. Epub 2024 Oct 31.
Bacillus Calmette-Guérin (BCG) is capable of enhancing the infiltration of immune cells into the tumour. However the temporal dynamics of immune cell patterns in patients receiving BCG instillation remains unclear.
Ninety-six patients who underwent intravesical BCG therapy, comprising 46 responders and 50 non-responders, were retrospectively enroled to explore the evolving immune landscape. This study involved a detailed examination of sequential samples collected before, during, and after BCG treatment to assess BCG's influence on the immune microenvironment, employing techniques such as immunohistochemistry, fluorescent multiplex immunohistochemistry, and mass spectrometry techniques.
Our study found that initial BCG instillation leads to enhanced immune cell infiltration, correlating with treatment efficacy, with responders exhibiting more pronounced increases. Non-responders experience a rise in immune cell infiltration and PD-L1 expression during the first instillation, which returns to baseline after treatment. In non-responders, BCG re-challenge fail to further increase immune cell infiltration into the tumour or improve patient outcomes. Strikingly, proteomics data revealed that GBP1 expression was induced by BCG treatment in non-responders.
Our findings demonstrated the induction of tumour PD-L1 expression by BCG in non-responders, and therefore provide insights for the combination of BCG and anti-PD1/anti-PD-L1 therapy.
卡介苗(BCG)能够增强免疫细胞向肿瘤内的浸润。然而,接受卡介苗灌注治疗的患者体内免疫细胞模式的时间动态变化仍不清楚。
回顾性纳入96例接受膀胱内卡介苗治疗的患者,其中46例有反应者和50例无反应者,以探索不断演变的免疫格局。本研究详细检查了在卡介苗治疗前、治疗期间和治疗后采集的系列样本,采用免疫组织化学、荧光多重免疫组织化学和质谱技术等评估卡介苗对免疫微环境的影响。
我们的研究发现,初次卡介苗灌注导致免疫细胞浸润增强,这与治疗效果相关,有反应者的增加更为明显。无反应者在首次灌注期间免疫细胞浸润和PD-L1表达增加,治疗后恢复至基线水平。在无反应者中,再次卡介苗刺激未能进一步增加免疫细胞向肿瘤内的浸润或改善患者预后。引人注目的是,蛋白质组学数据显示,无反应者经卡介苗治疗后GBP1表达被诱导。
我们的研究结果证明了卡介苗在无反应者中诱导肿瘤PD-L1表达,因此为卡介苗与抗PD1/抗PD-L1治疗联合应用提供了见解。